The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2019 | Bringing Dara into the first-line for multiple myeloma
Michael O’Dwyer, MD, PhD, from the National University of Ireland, Galway, Ireland, discusses the advantages of bringing daratumumab into the first-line setting as the CyBorD-Dara combination (cyclophosphamide, bortezomib and dexamethasone with daratumumab) for the treatment of multiple myeloma. Here, Prof. O’ Dwyer highlights how cyclophosphamide can activate macrophages, and therefore enhance antibody-dependent cellular phagocytosis. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
